home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2841.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
38 lines
Document 2841
DOCN M94A2841
TI Synergistic effect of recombinant CD4-immunoglobulin in combination with
azidothymidine, dideoxyinosine and 0.5 beta-monoclonal antibody on HIV
infection in vitro.
DT 9412
AU Ushijima H; Ando S; Kitamura T; Muller WE; Dept. of Microbiology,
Institute of Public Health, Tokyo, Japan.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):212 (abstract no. PB0277). Unique
Identifier : AIDSLINE ICA10/94369734
AB OBJECTIVE: To demonstrate the combination therapy of recombinant CD4
(rCD4) or CD4-immunoglobulin (rCD4-IgG) with other compounds is more
effective than monotherapy in vitro. MATERIALS AND METHODS: rCD4-IgG (or
rCD4), AZT, ddI and mouse MAb 0.5 beta (directed against the V3 loop
region of HIV-IIIB-gp120), were kindly provided. MT-4, MOLT-4,
MOLT-4/HIV-1, MOLT-4/HIV-2 and MOLT-4/SIV cells were used. Cell free
infection and cell-to-cell infection were conducted by using IIIB strain
with different combination- or mono-treatments. RESULTS: rCD4-IgG highly
inhibited the infections of HIV-1 than those of HIV-2 and SIV. The
combination with AZT, ddI or 0.5 beta MAb were more effective in
treatment at cell-free infection in vitro than each respective compound
alone. DISCUSSION: It is suggested that the combination therapy is more
beneficial in treatment of HIV-infected patients than monotherapy,
especially with respect to a reduction of the known side effects and the
formation of resistant HIV strains after treatment with nucleoside
analogues.
DE Animal Antibodies, Monoclonal/*PHARMACOLOGY Antigens,
CD4/IMMUNOLOGY/*PHARMACOLOGY Comparative Study
Didanosine/*PHARMACOLOGY Drug Synergism Human HIV Envelope Protein
gp120/*IMMUNOLOGY HIV-1/*DRUG EFFECTS/IMMUNOLOGY HIV-2/*DRUG EFFECTS
IgG/PHARMACOLOGY Mice Peptide Fragments/*IMMUNOLOGY Recombinant
Proteins/PHARMACOLOGY SIV/*DRUG EFFECTS Zidovudine/*PHARMACOLOGY
MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).